Table 2.

Univariable Cox regression analysis for MACE in Patients with AMI.

Characteristic	HR (95% CI)	p-Value
Ages, years	1.034 (1.016–1.051)	<0.001
Females, %	2.168 (1.405–3.346)	<0.001
New AMI, %	1.049 (0.600–1.837)	0.866
Previous histories
Stroke, %	1.311 (0.712–2.417)	0.385
Hypertension, %	0.872 (0.568–1.341)	0.534
Diabetes, %	1.295 (0.811–2.068)	0.279
Smoking, %	0.535 (0.349–0.822)	0.004
Systolic BP, mmHg	1.001 (0.991–1.011)	0.888
Diastolic BP, mmHg	0.994 (0.979–1.010)	0.473
Heart rate, beats/min	1.008 (0.996–1.020)	0.210
Creatinine, µmol/L	1.000 (0.999–1.000)	0.718
Total cholesterol, mmol/L	0.993 (0.963–1.024)	0.649
Low-density lipoprotein, mmol/L	0.965 (0.781–1.193)	0.745
High-density lipoprotein, mmol/L	0.956 (0.800–1.142	0.618
Triglycerides, mmol/L	0.892 (0.768–1.035)	0.132
Fasting glucose, mmol/L	1.036 (0.966–1.111)	0.328
Cardiac Troponins I, μg/L	1.000 (0.999–1.001)	0.528
ST-segment elevation, %	1.176 (0.766–1.805)	0.460
Killip II/III class, %	2.313 (1.323–4.044)	0.003
PCI, %	0.831 (0.523–1.320)	0.432
Medical treatment
Aspirin, %	0.408 (0.178–0.937)	0.034
Statin, %	0.309 (0.149–0.641)	0.002
Clopidogrel, %	1.241 (0.768–2.005)	0.377
Beta-blocker, %	0.591 (0.385–0.908)	0.016
Ticagrelor, %	0.572 (0.336–0.975)	0.040
ACEI/ARB, %	0.814 (0.529–1.251)	0.348

HR hazard ratio, CI confidence interval, MACE major adverse cardiac events, other abbreviations as in Table 1.